Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Crestor is “approvable”

Executive Summary

AstraZeneca receives "approvable" letter for Crestor (rosuvastatin) May 31, a month ahead of the 12-month review deadline. The company expected an "approvable" letter from FDA for the statin, whose 80 mg dose has been associated with rhabdomyolysis (1"The Pink Sheet" Feb. 4, p. 25)...

You may also be interested in...



AstraZeneca Crestor

AstraZeneca cholesterol agent Crestor (rosuvastatin) has a user fee action deadline in August, after the company submitted additional data on 10 mg to 40 mg doses to FDA Feb. 12. AstraZeneca received an "approvable" letter for Crestor May 31, 2002 (1"The Pink Sheet" June 10, 2002, In Brief)...

AstraZeneca Crestor Post-NDA Studies Focusing On 40 Mg Dose

AstraZeneca's ongoing trials of Crestor are focusing on 40 mg as the maximum dose of the cholesterol-lowering drug

AstraZeneca Crestor 80 Mg Dose Would Have Low Demand, CEO Suggests

AstraZeneca expects that an 80 mg strength of Crestor, if approved, would constitute a small proportion of the product's sales

Related Content

UsernamePublicRestriction

Register

PS039953

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel